Context Therapeutics is trading 7.03% up at $0.37 now in pre-market on September 28, 2026, with no company-specific announcement explaining the move identified.
- The latest located company update was September 9, when it announced the first patient dosed in its Phase 1 CT-202 trial.
- Broader market signals are mixed, with futures lower amid technology weakness and renewed geopolitical concerns; available evidence does not establish these as the cause of the pre-market rise.